Meranzin hydrate - CAS:5875-49-0

您当前的位置：

Meranzin hydrate (Synonyms:橙皮内酯水合物)

目录号 : KM14924 CAS No. : 5875-49-0 纯度 : 98%

Data Sheet SDS 产品使用指南

Meranzin hydrate，一种来自于中药柴胡疏肝散中的吸收的生物活性化合物，具有抗抑郁和抗动脉粥样硬化作用。

规格	价格	是否有货	数量
1mg		In-stock
5mg		In-stock
10mg		In-stock
25mg		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Davidigenin In-stock
Eloralintide In-stock
Anti-Mouse CXCL10 Antibody (1F11) In-stock
YL-365 In-stock
Aleniglipron In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Meranzin hydrate, an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS), possess anti-depression and anti-atherosclerosis effects.

体内研究

Meranzin hydrate (9-18 mg/kg; single dose) can improve depression like behavior and bradykinesia induced by acute forced swimming in rats by regulating the BDNF/p-mTOR signaling pathway and HTB loop activity related to growth hormone releasing peptide in the hippocampus.
Meranzin hydrate (18 mg/kg; single dose) can reduce depressive like behavior in wild-type mice based on FST and TST test results [1].
Meranzin hydrate (18 mg/kg; single dose) did not alleviate depression like behavior in GHSR knockout mice when evaluated by FST and TST results [1].
Meranzin hydrate (10 mg/kg; gavage; Daily; Significant antidepressant like and anti anxiety like effects were observed in chronic unpredictable mild stress (UCMS) induced depression rats for 7 consecutive days, which restored normal hypothalamic pituitary adrenal (HPA) axis function, increased expression of hippocampal brain-derived neurotrophic factor (BDNF), and repaired UCMS induced abnormal blood oxygen level dependent (BOLD) activation in the reward and limbic systems.

Animal Model:	Sprague-Dawley (8 rats per group; acute forced swimming-induced model)^[1]
Dosage:	9 mg/kg; 18 mg/kg
Administration:	single dose
Result:	Improved depression-like behavior (FST, OFT) and hypomotility (GE, IT) (all P<0.05). Significantly stimulated BDNF and p-mTOR protein expressions in the hippocampus (both P<0.01). Modulated activity in the hippocampus-thalamus-basal ganglia (HTB) circuits as measured by BOLD foci. Had its effect on FST and GE inhibited by ghrelin antagonist [D-Lys3]-GHRP-6 (P<0.05). Had its stimulation of hippocampal BDNF and p-mTOR expressions prevented by [D-Lys3]-GHRP-6 (P<0.01). Had its modulation of HTB circuit activity inhibited by [D-Lys3]-GHRP-6.

Animal Model:	Wild-type (8 mice per group)
Dosage:	18 mg/kg
Administration:	single dose
Result:	Alleviated depression-like behavior (FST, TST) in wild-type mice.

Animal Model:	Growth hormone secretagogue receptor knockout (GHSR KO)
Dosage:	18 mg/kg
Administration:	single dose
Result:	Showed no antidepressant effects in GHSR KO mice, with no observed changes in FST or TST outcomes.

Animal Model:	Wistar (adult male, 180−220 g, UCMS-induced depression model)
Dosage:	10 mg/kg
Administration:	i.g.; daily; 7 days
Result:	Significantly reduced immobility time in the forced swimming test (P < 0.001 vs UCMS group). Significantly increased sucrose preference index (P < 0.01 vs UCMS group). Significantly increased total distance travelled in the open-field test (P < 0.01 vs UCMS group). Significantly reduced plasma adrenocorticotropic hormone (ACTH) (P < 0.05 vs UCMS group), corticosterone (CORT) (P < 0.01 vs UCMS group), and acylated ghrelin (AG) (P < 0.01 vs UCMS group) levels, normalizing them to near control levels. Significantly increased brain-derived neurotrophic factor (BDNF) expression in the hippocampal dentate gyrus (P < 0.01 vs UCMS group). Attenuated UCMS-induced increased BOLD activation in reward system and limbic system brain regions, including the striatum, septal area, thalamus lateral nucleus group, bed nucleus of stria terminalis, hippocampus, midbrain superior colliculus, nucleus accumbens, and third ventricle. Increased BOLD activation in the right auditory cortex, right amygdaloid body, left sensory cortex, right third ventricle, and left temporal association cortex. Reversed UCMS-induced changes in BOLD signals in the right amygdaloid body and right visual cortex, and decreased BOLD signals in bilateral hypothalamus preoptic regions.

分子式

C₁₅H₁₈O₅

分子量

278.30

CAS号

5875-49-0

中文名称

橙皮内酯水合物

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

2-8°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性数据

In Vitro:

DMSO : 100 mg/mL (359.32 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.5932 mL	17.9662 mL	35.9324 mL
5 mM	0.7186 mL	3.5932 mL	7.1865 mL
10 mM	0.3593 mL	1.7966 mL	3.5932 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline

Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.98 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
2.

请依序添加每种溶剂： 10% DMSO → 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.98 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
3.

请依序添加每种溶剂： 10% DMSO → 90% corn oil

Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.98 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

纯度： 98%

Data Sheet

SDS

产品使用指南

暂无相关参考文献

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

动物实验计算换算器

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系客服为您提供正确的澄清溶液配方）

% DMSO

% Tween 80

% ddH₂O

% DMSO

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系客服）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

配置后的溶液总体积：

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 0 篇科研文献

The molarity calculator equation

The dilution calculator equation

动物实验计算换算器